Eli Lilly & Co. vs. Ultragenyx Pharmaceutical Inc.
Eli Lilly & Co. (LLY) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| LLY | RARE | |
|---|---|---|
| Market Cap | $1.09 trillion | $2.65 billion |
| Revenue (TTM) | — | $717.21 million |
| Net Income (TTM) | — | $-585,969,000 |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | RARE | |
|---|---|---|
| Price / Book | — | -9.10 |
| Price / Sales | — | 3.69 |
LLY and RARE split the valuation factors evenly.
Profitability
| LLY | RARE | |
|---|---|---|
| Net Margin | — | -81.70% |
| Return on Equity | — | 201.36% |
LLY and RARE split the profitability factors evenly.
Risk & Sentiment
| LLY | RARE | |
|---|---|---|
| Short Interest | 1.29% | 5.60% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, RARE overview, RARE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.